Eip Pharma

• John Alam

  Ceo

Sources: reporter.nih.gov

• National Institute on Aging

  R01, A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB), R01AG080536, US$6.1m, 2023–2026, 11 Mar 2025

Sources: reporter.nih.gov

• Alzheimer's disease target and drug discovery by leveraging multiomics and electronic health data

  Shares or equity, 8 Oct 2026

• Late-onset depression predicts cognitive impairment and subsequent dementia among older adults with major depressive disorder: findings from UK Biobank and primary care linked data

  Consulting or advice, Fees or honoraria, 10 Mar 2026

Sources: pubmed.ncbi.nlm.nih.gov